Monthly Archives: May 2012

NEW YORK, NY--(Marketwire -05/14/12)- Biotech companies are looking to cash in on the anti-obesity drug market. The race to bring the first weight-loss pill to the market is heating up as Arena Pharmaceuticals weight-loss pill (Lorcaserin) recently gained the backing of an FDA advisory panel. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on VIVUS, Inc. (VVUS) and Roche Holding Ltd. (RHHBY.PK). Access to the full company reports can be found at: http://www.ParagonReport.com/VVUS http://www.ParagonReport.com/RHHBY Arena is currently competing with Vivus and Orexigen Therapeutics to bring the first anti-obesity drug to the market in nearly 13 years. All three of the companies' drugs were previously turned down by the FDA. FDA advisers last week voted 18-4 that the benefits of Arena's Lorcaserin outweigh the health risks. According to recent numbers from the Center for Disease Control and Prevention over 78 million adults in the U.S. are obese. Obesity significantly raises the risks for health problems such as diabetes, heart attacks, and strokes. It is estimated that obesity costs the U.S. economy $147 billion a year in medicals costs and lost productivity. Paragon Report releases regular market updates on the Biotech Industry so investors can stay … Continue reading →

Doctors usually give breast cancer patients several cancer drugs; they claim that these drugs produce better results than treatment with just a single drug. Now researchers have found that two powerful drugs can cure breast cancer. Researchers from the Massachusetts Institute of Technology(MIT)have discovered thaterlotinib and doxorubicin have the capability to kill a particularly malignant type of breast cancer cells. Researchers had been studying complex cell-signalling pathways that control cells' behaviour: how much they grow, when they divide, when they die. In cancer, the cells grow uncontrolled and abnormally in the body. Researchers believed that the only way to switch a cancerous cell into a less malignant state is by using different combinations of cancer drugs. They tested different combinations of 10 DNA-damaging drugs and a dozen drugs that inhibit different cancerous pathways, using different timing schedules. Like us on Facebook Of all combinations they tried, they saw the best results with pretreatment using erlotinib followed by doxorubicin, a common chemotherapy agent. To prove that erlotinib and doxorubicin could kill cancer cells, the researchers conducted an experiment on mice that had tumours. A group of mice was given erlotinib and doxorubicin in different durations. Another group was given only chemotherapy … Continue reading →

EMPLOYERS in Circular Head have had trouble with drugs in the workforce, according to Mayor Daryl Quilliam. His comments come in the wake of a $300,000 cannabis bust at Smithton. "We have people that are wanting to employ people and drugs are not always an issue, but they're an issue often and people get really frustrated not knowing what to do," he said. "People employ people and they try to stress that they don't want drugs in the workforce, then a bit later they find that some of these people are on drugs. "A lot of guys that work on farms, it's an issue there. "I would think it's everywhere though to be quite honest." Cr Quilliam said it was an issue that affected most regional areas, but wasn't spoken about much. "I think drugs here are a bit like other places, they are far more prevalent than I'd like to think they would be," he said. "We're certainly concerned and would rather not have drugs involved with young people at all. "It's a shocking thing, there's no doubt about that. Excerpt from: `Drugs an issue in CH workforce' … Continue reading →

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- The transition from discovery and development to drug commercialization requires an entirely different set of skills, as both large and small pharmaceutical and biotech companies have found. And the costs of successfully planning and executing a global drug launch must now cover more regions and more functional groups than ever before, according to findings from consulting firm Cutting Edge Information. Complex pieces of the global launch puzzle such as regulatory submission, managed markets planning, and launch sequencing must be coordinated carefully. Each piece has a large impact on initial market reception and can drag down or drive up revenue results. These commercial steps require expertise quite different from earlier clinical trial phases; trying to shoehorn clinical experience into commercial needs invites disaster. Licensing and co-development deals can bridge the gap. Cutting Edge Informations recent study, Business Development and Licensing: Strengthening Pipelines and Managing Relationships, profiles how a development-oriented company with a promising compound primed for market, but without commercialization infrastructure, can leverage another companys experience to continue preparing the new product for launch. Collaborating with a company that has deep experience with regulatory submission and launch in major and emerging markets will save time and … Continue reading →